JUNO Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) Investors

Wednesday, November 1, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, Oct. 31, 2017 /PRNewswire/ --áKyros Law Offices is alerting investors of JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) that

it is investigating legal claims against the company for possible securities fraud violations committed by JUNO THERAPEUTICS, INC. (NASDAQ: JUNO).

JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) investors are urged to contact our law firm immediately to protect their rights. Visit ourá

JUNO Shareholder Lawsuit website or call 1-800-934-2921 to speak to someone about your case.

The investigation concerns possible violations of securities law committed by JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) management that has led to significant losses to investors. These possible violations stem from allegations from a recent lawsuit that JUNO executives may have misled investors about the prospects of a new cancer drug, JCAR015.

Kyros Law Offices urges JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) investorsáto contact our law firm immediately to protect their rights. Visit ouráJUNO Shareholder Lawsuit websiteáor call 1-800-934-2921 to find out if you have a case.

Kyros Lawáspecializes in a wide range of complex litigation, mass torts, and corporate governance matters, including the representation of whistleblowers, shareholders and consumers in securities fraud, false claims act and class actions. Our lawyers have been responsible for recovering hundreds of millions of dollars for our clients throughoutáthe United States,áAfrica,áAsiaáandáEurope. Visit ouráwebsiteáto learn more about our firm.

View original content:http://www.prnewswire.com/news-releases/juno-investor-alert-kyros-law-is-investigating-legal-claims-on-behalf-of-juno-therapeutics-inc-nasdaq-juno-investors-300546928.html

SOURCE Kyros Law



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store